Nashville-based Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) reported that ifetroban, its thromboxane A2 receptor antagonist, met the primary safety endpoint in a Phase IIa trial enrolling patients with high-risk solid tumors, with an exploratory signal showing zero metastasis-related deaths in the ifetroban arm versus three in the placebo arm. The finding, albeit preliminary, adds weight to the hypothesis that blocking platelet-mediated tumor cell shielding could reduce distant metastatic spread.
The randomized, double-blind, placebo-controlled Phase IIa trial enrolled 29 patients with solid tumors — including breast, lung, pancreatic, soft tissue, bladder, and renal cancers — defined as carrying at least a 50% probability of recurrence within five years of diagnosis. Ifetroban was administered after completion of all primary cancer therapies and surgical procedures, with patients receiving treatment for 12 months and followed for an additional 12 months. The study enrolled 19 patients to the ifetroban arm and 10 to placebo.
The primary safety endpoint was met: treatment-related adverse event rates were similar between arms, no serious adverse events above Grade 3 were attributed to study treatment in either group, and discontinuation rates did not differ statistically. On the prespecified secondary efficacy endpoint — distant metastatic recurrence at 12 months after therapy completion — 17% of ifetroban-treated patients experienced recurrence compared with 50% in the placebo arm (p=0.091). Three deaths due to distant metastatic disease occurred in the placebo arm; none occurred in the ifetroban arm (p=0.037). The trial was explicitly not powered for efficacy, and these findings are best interpreted as hypothesis-generating rather than confirmatory.